Intrahepatic HBV-DNA of the patients with HBs seroclearance by lamivudine

The ideal goal for the treatment of chronic hepatitis B is the complete eradication of HBV. With prolonged lamivudine therapy, the HBeAg seroconversion rate can be increased. It has been reported that in some Caucasian patients, lamivudine induced not only HBeAg seroconversion, but also HBsAg seroconversion. However, such reports about Asian patients are rare. We report here on two Korean patients who experienced HBsAg seroclearance by lamivudine, and they had different HBV-DNA liver statuses. They were 35 and 30 years old males and they were treated with lamivudine for 36 and 18 months, respectively. As the HBeAg and HBsAg were lost, both patients developed anti-HBs. Liver biopsy revealed improvement of inflammation and fibrosis in one patient. Even though the other patient also developed anti-HBs, HBV-DNA was still detected in the liver tissue. Our cases show that lamivudine can bring HBsAg seroclearance in Korean patients suffering with chronic hepatitis B, but further research is needed to eliminate HBV-DNA in liver tissue.(Korean J Med 71:S998-S1002, 2006)

[1]  Y. N. Park,et al.  Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. , 2005, Journal of hepatology.

[2]  M. Yuen,et al.  HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection , 2004, Journal of Clinical Microbiology.

[3]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[4]  M. Yuen,et al.  Current and future antiviral agents for chronic hepatitis B. , 2003, The Journal of antimicrobial chemotherapy.

[5]  S. Cheung,et al.  Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B , 2003, Hepatology.

[6]  D. Domenighini,et al.  Real‐time quantitation of hepatitis B virus (HBV) DNA in tumorous and surrounding tissue from patients with hepatocellular carcinoma , 2002, Journal of medical virology.

[7]  M. Yuen,et al.  Long‐term follow‐up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis‐related complications , 2001, Hepatology.

[8]  G. Lau,et al.  Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer , 1997, Hepatology.

[9]  K. Fleming,et al.  Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients. , 1993, Journal of clinical pathology.

[10]  C. Chu,et al.  Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study , 1991, Hepatology.

[11]  B. McMahon,et al.  The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. , 1985, The Journal of infectious diseases.

[12]  R. Sampliner,et al.  The Liver Histology and Frequency of Clearance of the Hepatitis B Surface Antigen (HBsAg) in Chronic Carriers , 1979, The American journal of the medical sciences.